Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 90

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 90
---
 persons have represented to the Company that they exercise sole voting power and sole investment power with respect to their shares. (2) Based solely on the Schedule 13G filed with the SEC on January 8, 2025 by BlackRock, Inc. (“BlackRock”). BlackRock reported having sole voting power with respect to 5,160,440 shares, shared voting power with respect to 0 shares, sole investment power with respect to 5,466,102 shares and shared investment power with respect to 0 shares. (3) Based in part on Amendment No. 2 to the Schedule 13G filed with the SEC on November 14, 2024 by Redmile Group, LLC (“Redmile Group”). Redmile Group’s beneficial ownership of the common stock of the Company is comprised of shares owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, including Redmile Biopharma Investments III, L.P., which shares may be deemed beneficially owned by Redmile Group as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group. Redmile Group and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Redmile Group reported beneficial ownership of 4,892,902 shares of the Company's common stock. On March 11, 2024, we completed a registered securities offering (the "March 2024 Offering") in which entities affiliated with Redmile Group, including Redmile Biopharma Investments III, L.P., purchased pre-funded warrants to purchase shares of common stock (the “Pre-funded Warrants”), of which 1,324,740 Pre-funded Warrants remained outstanding as of the Record Date. The Pre-funded Warrants are immediately exercisable at a price of price of $0.0001 per share to the extent such exercise would not cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder’s for purposes of Section 13(d) of the Exchange Act) to exceed 9.99% of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates and any